CL2012001110A1 - Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar. - Google Patents

Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar.

Info

Publication number
CL2012001110A1
CL2012001110A1 CL2012001110A CL2012001110A CL2012001110A1 CL 2012001110 A1 CL2012001110 A1 CL 2012001110A1 CL 2012001110 A CL2012001110 A CL 2012001110A CL 2012001110 A CL2012001110 A CL 2012001110A CL 2012001110 A1 CL2012001110 A1 CL 2012001110A1
Authority
CL
Chile
Prior art keywords
paliperidone palmitate
schizophrenia
missed
administering
patient
Prior art date
Application number
CL2012001110A
Other languages
English (en)
Spanish (es)
Inventor
Peter H Lewyn-Briscoe
Mayer Cristiana Gassmann
David W Hough
Bart M M Remmerie
Mahesh N Gopal Srih Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43302985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2012001110A1 publication Critical patent/CL2012001110A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012001110A 2009-10-30 2012-04-27 Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar. CL2012001110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
CL2012001110A1 true CL2012001110A1 (es) 2012-10-19

Family

ID=43302985

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001110A CL2012001110A1 (es) 2009-10-30 2012-04-27 Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar.

Country Status (12)

Country Link
US (2) US20110105536A1 (enExample)
EP (1) EP2493473A1 (enExample)
JP (2) JP2013509435A (enExample)
KR (1) KR20120116401A (enExample)
CN (1) CN102802631A (enExample)
AU (2) AU2010313290A1 (enExample)
BR (1) BR112012010195A2 (enExample)
CA (1) CA2742393A1 (enExample)
CL (1) CL2012001110A1 (enExample)
MX (1) MX2012005083A (enExample)
NZ (1) NZ599558A (enExample)
WO (1) WO2011053829A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
ES2802299T3 (es) * 2015-04-07 2021-01-18 Janssen Pharmaceuticals Inc Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US12431230B2 (en) 2019-09-25 2025-09-30 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
EP4208217A1 (en) * 2020-09-02 2023-07-12 Janssen Pharmaceutica NV Pre-filled syringe with optimized stopper placement
DK4025188T3 (da) 2020-11-30 2024-03-04 Janssen Pharmaceutica Nv Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
EP4025189B1 (en) 2020-11-30 2024-06-05 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4385564A3 (en) 2020-11-30 2024-10-09 JANSSEN Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
EP4308077A1 (en) * 2021-03-17 2024-01-24 MedinCell S.A. Long acting injectable formulation comprising risperidone and biodegradable polymers
CA3229731A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
TW200825077A (en) * 2006-08-14 2008-06-16 Teva Pharma Crystal forms of 9-hydroxy-risperidone (paliperidone)
SI2234617T2 (sl) 2007-12-19 2025-05-30 Janssen Pharmaceutica Nv Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje

Also Published As

Publication number Publication date
AU2015243103A1 (en) 2015-11-05
EP2493473A1 (en) 2012-09-05
NZ599558A (en) 2014-09-26
CA2742393A1 (en) 2011-05-05
JP2013509435A (ja) 2013-03-14
CN102802631A (zh) 2012-11-28
BR112012010195A2 (pt) 2016-04-26
MX2012005083A (es) 2012-09-28
WO2011053829A1 (en) 2011-05-05
AU2010313290A1 (en) 2012-05-17
US20110105536A1 (en) 2011-05-05
US20130331402A1 (en) 2013-12-12
JP2016102123A (ja) 2016-06-02
KR20120116401A (ko) 2012-10-22

Similar Documents

Publication Publication Date Title
CL2012001110A1 (es) Régimen de dosificación para administrar palmitato de paliperidona inyectable de depósito a un paciente que necesite tratamiento psiquiátrico que haya sido tratado con palmitato de paliperidona y que ha omitido la próxima dosis de mantenimiento programada; metodo para tratar psicosis, esquizofrenia y trastorno bipolar.
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
NZ702663A (en) Nuclear transport modulators and uses thereof
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
BR112012031359A2 (pt) sistema e método de planejamento e monitoramento da utilização de doses múltiplas de radiofármacos em injetores de radiofármacos
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
UA118732C2 (uk) Схема введення пропущених доз естерів паліперидону тривалої дії для ін'єкційного застосування
FR2979539B1 (fr) Composition sterile dermo-injectable
IN2014CN00315A (enExample)
CO6771410A2 (es) Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad o prediabetes
BR112014025737A2 (pt) método para administrar um agente terapêutico, método para prevenir a entrada de um agente terapêutico, método para modular a velocidade de liberação de um agente terapêutico, agente terapêutico, formas de dosagem, método de tratamento de uma doença e kit de partes
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
MX2022000746A (es) Dimetilfumarato y regimenes de vacunacion.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
EP2692351A4 (en) ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT
CR20150240A (es) Compuesto reforzado de fibra de vidrio o cuarzo y resina de fotocurado, proceso para reconstrucción de piezas dentales y método de aplicación del compuesto